Morphologic and Molecular Landscape of Pancreatic Cancer Variants as the Basis of New Therapeutic Strategies for Precision Oncology

• Published in: International journal of molecular sciences 2020-11, Vol.21 (22), p.8841
• Main Authors: Bazzichetto, Chiara, Luchini, Claudio, Conciatori, Fabiana, Vaccaro, Vanja, Di Cello, Ilaria, Mattiolo, Paola, Falcone, Italia, Ferretti, Gianluigi, Scarpa, Aldo, Cognetti, Francesco, Milella, Michele
• Format: Article
• Language: English
• Subjects: Carcinoma, Pancreatic Ductal - classification; Carcinoma, Pancreatic Ductal - genetics; Carcinoma, Pancreatic Ductal - pathology; Carcinoma, Pancreatic Ductal - therapy; Genomics; Germ-Line Mutation; Humans; Mutation; Neoplasm Proteins - genetics; Pancreatic Neoplasms - classification; Pancreatic Neoplasms - genetics; Pancreatic Neoplasms - pathology; Pancreatic Neoplasms - therapy; Precision Medicine; Review
• ISSN: 1422-0067; 1422-0067
• DOI: 10.3390/ijms21228841

To date, pancreatic cancer is still one of the most lethal cancers in the world, mainly due to the lack of early diagnosis and personalized treatment strategies. In this context, the possibility and the opportunity of identifying genetic and molecular biomarkers are crucial to improve the feasibility of precision medicine. In 2019, the World Health Organization classified pancreatic ductal adenocarcinoma cancer (the most common pancreatic tumor type) into eight variants, according to specific histomorphological features. They are: colloid carcinoma, medullary carcinoma, adenosquamous carcinoma, undifferentiated carcinoma, including also rhabdoid carcinoma, undifferentiated carcinoma with osteoclast-like giant cells, hepatoid carcinoma, and signet-ring/poorly cohesive cells carcinoma. Interestingly, despite the very low incidence of these variants, innovative high throughput genomic/transcriptomic techniques allowed the investigation of both somatic and germline mutations in each specific variant, paving the way for their possible classification according also to specific alterations, along with the canonical mutations of pancreatic cancer ( , , , ). In this review, we aim to report the current evidence about genetic/molecular profiles of pancreatic cancer variants, highlighting their role in therapeutic and clinical impact.